Abstract
Non-GIST soft tissue sarcomas are a heterogeneous grouping of mesenchymal tumors that comprise less than 1% of adult malignancies. Treatment continues to be based on cytotoxic chemotherapy regimens. However, characterization of the molecular pathway deregulations that drive these tumors has led to the emergence of more customized treatment options. In this review, we focus on the multitude of molecular inhibitors targeting angiogenesis and cell cycle pathways being tested in clinical trials.
Keywords:
angiogenesis inhibitors; cell cycle inhibitors; non-GIST soft tissue sarcoma; targeted therapy.
© 2014 Wiley Periodicals, Inc.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / therapeutic use*
-
Cell Cycle / drug effects
-
Gastrointestinal Neoplasms / blood supply
-
Gastrointestinal Neoplasms / drug therapy
-
Gastrointestinal Neoplasms / metabolism
-
Gastrointestinal Neoplasms / pathology
-
Gastrointestinal Stromal Tumors / blood supply
-
Gastrointestinal Stromal Tumors / drug therapy
-
Gastrointestinal Stromal Tumors / metabolism
-
Gastrointestinal Stromal Tumors / pathology
-
Humans
-
Molecular Targeted Therapy
-
Sarcoma / blood supply
-
Sarcoma / drug therapy*
-
Sarcoma / metabolism
-
Sarcoma / pathology
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents